Jeffrey J. Quinn

Jeffrey J. Quinn

Auto-generated profile, based on publicly available information

Jeffrey J. Quinn

Beam Therapeutics, Cambridge, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2022 in Cell
Verified
Journal Article
Open access
DYDian Yang
Dian Yang
MJMatthew G. Jones
Matthew G. Jones
SNSantiago Naranjo
Santiago Naranjo
WRWilliam M. Rideout
William M. Rideout
KMKyung Hoi (Joseph) Min
Kyung Hoi (Joseph) Min
JWJonathan S. Weissman
Jonathan S. Weissman
Tumor evolution is driven by the progressive acquisition of genetic and epigenetic alterations that enable uncontrolled growth and expansion to neighboring and distal tissues. The study of phylogenetic relationships between cancer cells provides key insights into these processes. Here, we introduced an evolving lineage tracing system with a single-cell RNA-seq readout into a mouse model of Kras;Trp53(KP)-driven lung adenocarcinoma and tracked tumor evolution from single transformed cells to metastatic tumors at unprecedented resolution. We found that loss of the initial, stable alveolar-type2-like state was accompanied by transient increase in plasticity. This was followed by adoption of distinct transcriptional programs which enable rapid expansion and ultimately clonal sweep of stable subclones capable of metastasizing. Finally, tumors develop through stereotypical evolutionary trajectories, and perturbing additional tumor suppressors accelerates progression by creating novel trajectories. Our study elucidates the hierarchical nature of tumor evolution, and more broadly enables in-depth studies of tumor progression.

26 February 2021 in Science
Verified
Journal Article
Closed access
JQJeffrey J. Quinn
Jeffrey J. Quinn
MJMatthew G. Jones
Matthew G. Jones
RORoss A. Okimoto
Ross A. Okimoto
SNShigeki Nanjo
Shigeki Nanjo
MCMichelle M. Chan
Michelle M. Chan
JWJonathan S. Weissman
Jonathan S. Weissman
Following cancer through the body: The heterogeneity of mammalian tumors has been well documented, but it remains unknown how differences between individual cells lead to metastasis and spread throughout the body. Quinn et al. created a Cas9-based lineage tracer and used single-cell sequencing to generate phylogenies and follow the movement of metastatic human cancer cells implanted in the lung of a mouse xenograph model. Using this model, they found that within the same cell line, cancer cells exhibited diverse metastatic phenotypes. These subclones exhibited differential gene expression profiles, some of which were previously associated with metastasis. Science , this issue p. eabc1944

10 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
IAIrina Arnaoutova
Irina Arnaoutova
YAYvonne Aratyn-Schaus
Yvonne Aratyn-Schaus
LZLisa Zhang
Lisa Zhang
MPMichael S. Packer
Michael S. Packer
HCHung-Dar Chen
Hung-Dar Chen
JCJanice Y. Chou
Janice Y. Chou
Glycogen storage disease type-Ia patients, deficient in the G6PC1 gene encoding glucose-6-phosphatase-α, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the pathogenic G6PC1-R83C variant displays the phenotype of glycogen storage disease type-Ia and dies prematurely. We evaluate the efficacy of BEAM-301, a formulation of lipid nanoparticles containing a newly-engineered adenine base editor, to correct the G6PC1-R83C variant in huR83C mice and monitor phenotypic correction through one year. BEAM-301 can correct up to ~60% of the G6PC1-R83C variant in liver cells, restores blood glucose control, improves metabolic abnormalities of the disease, and confers long-term survival to the mice. Interestingly, just ~10% base correction is therapeutic. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for homozygous and compound heterozygous glycogen storage disease type-Ia patients carrying the G6PC1-R83C variant.